![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Publisher: Adis International
ISSN: 1173-8324
Source: Inpharma, Vol.1, Iss.1632, 2008-01, pp. : 10-10
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Eptifibatide keeps pace with abciximab in STEMI
Inpharma, Vol. 1, Iss. 1613, 2007-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Abciximab invaluable for PCI in CHD in the UK
Inpharma, Vol. 1, Iss. 1371, 2003-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Abciximab invaluable for PCI in CHD in the UK
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 396, 2003-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Clopidogrel is clearly a winner for STEMI, before and after PCI
Inpharma, Vol. 1, Iss. 1504, 2005-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Abciximab not so SWEET following PCI in CAD, diabetes
Inpharma, Vol. 1, Iss. 1476, 2005-01 ,pp. :